Skip to content

Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer

Pilot Trial of the Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02801734
Acronym
EQUIP
Enrollment
69
Registered
2016-06-16
Start date
2016-08-01
Completion date
2017-12-31
Last updated
2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Lung Cancer

Brief summary

i. Project Background Patients with advanced lung cancer have a high symptom burden and low quality of life. Early palliative care improves patient outcomes in newly diagnosed advanced lung cancer patients, but previously tested models are not feasible for widespread adoption. Hence, the aim of this study is to pilot a more sustainable nurse-led intervention - Enhancing Quality of life in Patients (EQUIP). ii. Hypothesis / Aim The aims of this study are three-fold. Firstly, the investigators aim to determine the feasibility and acceptability of the EQUIP intervention itself. Secondly, the investigators aim to obtain a tentative estimate of efficacy of the EQUIP intervention. Thirdly, the investigators aim to determine the data completion rate of patient reported outcome measures in the context of the EQUIP trial. iii. Methods Patients with newly diagnosed stage 3 or stage 4 lung cancer will be recruited and randomized to the EQUIP intervention or usual care (control) group. Patients randomized to the EQUIP intervention group will receive four face-to-face sessions with a palliative care nurse. The content of these educational sessions will equip patients with the knowledge and skills to manage the three commonest symptoms of fatigue, breathlessness and anxiety. All participants will complete the Functional Assessment of Cancer Therapy - Lung (FACT-L), the Hospital Anxiety and Depression Scale (HADS) and the stigma subscale at four time points: baseline, 4, 8 and 12 weeks after recruitment. Measures of healthcare use will also be recorded. Additionally, participants in the intervention group will complete a feedback survey after each intervention session. A total sample of 60 patients (30 in each arm) will be recruited. Clinical Significance If successful, this study will lead to a larger scale phase III trial which tests various components of the EQUIP intervention, in order to develop a sustainable and effective model for the provision of palliative care to advanced lung cancer patients.

Interventions

OTHEREQUIP

Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.

Sponsors

Duke-NUS Graduate Medical School
CollaboratorOTHER
National Cancer Centre, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Has stage 3 or 4 lung cancer * ECOG 0,1 or 2 * Able and willing to participate in the EQUIP programme

Exclusion criteria

\- Unable to communicate in English or Mandarin

Design outcomes

Primary

MeasureTime frameDescription
Quality of life4 weeksPatient quality of life will be measured by the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire.
Psychological distress4 weeksPsychological distress will be measured by the Hospital Anxiety and Depression Scale (HADS).

Secondary

MeasureTime frame
Number of hospital admissions6 months
Number of participants with referral to palliative care services6 months
Number of visits to the emergency department6 months

Other

MeasureTime frame
Number of participants who died at home1 year
Number of participants with anti-cancer therapy in the last 4 weeks of lifeLast four weeks of life
Overall survival1 year

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026